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Abstract
Corticosteroid-binding globulin (CBG) transports glucocorticoids in blood and is a 
serine protease inhibitor family member. Human CBG has a reactive center loop 
(RCL) which, when cleaved by neutrophil elastase (NE), disrupts its steroid-binding 
activity. Measurements of CBG levels are typically based on steroid-binding capacity or 
immunoassays. Discrepancies in ELISAs using monoclonal antibodies that discriminate 
between intact vs RCL-cleaved CBG have been interpreted as evidence that CBG with 
a cleaved RCL and low affinity for cortisol exists in the circulation. We examined the 
biochemical properties of plasma CBG in samples with discordant ELISA measurements 
and sought to identify RCL-cleaved CBG in human blood samples. Plasma CBG-binding 
capacity and ELISA values were consistent in arterial and venous blood draining skeletal 
muscle, liver and brain, as well as from a tissue (adipose) expected to contain activated 
neutrophils in obese individuals. Moreover, RCL-cleaved CBG was undetectable in 
plasma from critically ill patients, irrespective of whether their ELISA measurements 
were concordant or discordant. We found no evidence of RCL-cleaved CBG in plasma 
using a heat-dependent polymerization assay, and CBG that resists immunoprecipitation 
with a monoclonal antibody designed to specifically recognize an intact RCL, bound 
steroids with a high affinity. In addition, mass spectrometry confirmed the absence of 
NE-cleaved CBG in plasma in which ELISA values were highly discordant. Human CBG 
with a NE-cleaved RCL and low affinity for steroids is absent in blood samples, and CBG 
ELISA discrepancies likely reflect structural differences that alter epitopes recognized by 
specific monoclonal antibodies.
Introduction
Corticosteroid-binding globulin (CBG) transports 
glucocorticoids and progesterone in human blood and 
regulates their access to target tissues (Hammond 2016a). 
Human CBG is also known as SERPINA6 because it shares 
structural similarity with clade A serine proteinase inhibitor 
(SERPINA) family members (Hammond et  al. 1987). 
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Many SERPINAs inhibit proteases released during 
infections and inflammation by ensnaring them after 
proteolysis of an exposed reactive center loop region 
(RCL) that is characteristic of the SERPIN structure 
(Gettins & Olson 2016). While CBG is not known to 
inhibit proteases, its RCL is cleaved by neutrophil elastase 
(NE) (Hammond et al. 1990), chymotrypsin (Lewis & Elder 
2014) and Pseudomonas aeruginosa elastase (Simard et al. 
2014), causing a conformational change that disrupts CBG 
steroid-binding activity (Simard et al. 2015). Proteolysis of 
CBG appears to occur during the onset of inflammation 
(Hill et al. 2016) and is thought to increase the amount 
of ‘free’ or non-protein-bound glucocorticoids locally, at 
sites of inflammation (Hammond 2016b).
Plasma CBG levels were first determined using 
a variety of radio-ligand saturation assays that 
can also be used to examine its steroid-binding 
properties (Hammond & Lahteenmaki 1983). The first 
immunoassays for human CBG measurements relied 
on the use of polyclonal antibodies and radiolabeled 
CBG (Robinson et al. 1985). Plasma CBG concentrations 
measured by radioimmunoassay (RIAs) correlate well 
with measurements of its cortisol-binding capacity, 
except in samples containing CBG variants with 
abnormal steroid-binding properties (Robinson & 
Hammond 1985, Smith et  al. 1992, Emptoz-Bonneton 
et  al. 2000, Perogamvros et  al. 2010). More recently, 
ELISAs have been introduced that rely on the use of 
polyclonal antibodies as the immobilization reagent 
and monoclonal antibodies that recognize specific 
epitopes on the surface of CBG for its detection (Lewis 
et  al. 2003, Lewis & Elder 2011). One of these ELISAs 
employs a monoclonal antibody (12G2) that detects an 
epitope that is unperturbed by structural changes caused 
by RCL proteolysis (Lewis et al. 2003), and comparisons 
between plasma CBG values obtained using this ELISA 
and a cortisol-binding capacity assay have been used to 
identify CBG variants with abnormal steroid-binding 
activity (Hill et  al. 2012, Simard et  al. 2015). Another 
ELISA has been developed based on the use of a detection 
monoclonal antibody (9G12) raised against a synthetic 
polypeptide that spans the RCL, and its epitope is lost 
when the RCL is cleaved by NE (Lewis & Elder 2011). 
When plasma CBG levels measured in these two 
different ELISAs are compared in healthy individuals 
(Lewis & Elder 2011, 2013) and patient groups (Nenke 
et  al. 2015, 2016a,b,c, 2017a), discrepancies in values 
have been interpreted as evidence for the presence of 
CBG with a NE-cleaved RCL and low affinity for cortisol, 
but direct evidence for this is lacking.
We have therefore examined discrepancies in these 
ELISA measurements using several biochemical approaches 
and sought to identify RCL-cleaved forms of human CBG 
with low affinity for steroids in plasma from patients with 
inflammation and abnormally low CBG levels.
Materials and methods
Plasma samples
A subset of 20 plasma samples from the CROATIA-Korcula 
cohort described in a previously published GWAS (Bolton 
et  al. 2014) were selected to represent the discordancy 
observed between CBG-binding assay and ELISA values 
(10 samples were discordant in the 9G12 ELISA) and 
subsequently reanalyzed. The demographics for the 
subset of CROATIA-Korcula samples utilized in this study 
are as follows: concordant (age 58 ± 12 years, seven males 
and three females) and discordant (age 52 ± 15 years, two 
males and eight females), respectively.
Arterial and venous (from veins draining skeletal 
muscle, adipose, liver and brain) plasma samples from 
healthy lean individuals or obese patients were obtained 
from two published studies (for internal jugular Kilgour 
et al. 2015 and hepatic vein samples Stimson et al. 2011, 
respectively) and one unpublished study (for samples from 
veins draining forearm skeletal muscle and abdominal 
subcutaneous adipose tissue, using previously published 
techniques Hughes et  al. 2012). Samples were obtained 
during steady state D4-cortisol ± D2-cortisone tracer 
infusions and before any interventions. Blood flow was 
measured in indocyanine green infusion (liver), Xenon 
washout (adipose), venous occlusion plethysmography 
(skeletal muscle) and magnetic resonance angiography 
(internal jugular). Net uptake/release across tissues was 
calculated as arterio-venous difference in concentration 
multiplied by blood flow. Inclusion/exclusion criteria were 
as previously published (Stimson et al. 2011, Kilgour et al. 
2015), and subject characteristics are in Supplementary 
Table  1 (see section on supplementary data given at 
the end of this article). Ethical committee approval and 
written informed consent were obtained.
In addition, 146 plasma samples were obtained 
for analysis from patients admitted to the medical-
surgical adult Intensive Care Unit (ICU) of Attikon 
University Hospital. Severe sepsis and septic shock were 
defined according to the SCCM/ESICM/ACCP/ATS/SIS 
international sepsis definitions (Levy et  al. 2003). 
Exclusion criteria were age less than 18 years; mechanical 
ventilation for more than 48 h before ICU admission; 
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no intubation and mechanical ventilation during ICU stay; 
do-not-resuscitate clinical conditions; brain-death upon 
ICU entry; prior or current glucocorticoid use and HIV 
infection. ICU samples analyzed in the current study were 
collected as part of a larger protocol that was approved 
by the hospital’s ethics committee, and informed consent 
was obtained from patients’ relatives.
Measurements of CBG
Measurements of the cortisol-binding capacity of human 
CBG and its steroid-binding affinity by Scatchard analysis 
were performed using [3H]-cortisol or [3H]-corticosterone 
(PerkinElmer Life Sciences), as described (Hammond & 
Lahteenmaki 1983).
The 12G2 and 9G12 ELISAs of CBG in human blood 
samples have been described (Lewis et  al. 2003, Lewis 
& Elder 2011). Blood samples or purified CBG were 
diluted appropriately, and plasma with a known CBG 
concentration, based on cortisol-binding capacity, was 
serially diluted for ELISA standards.
Included within these assays are two reference plasma 
samples, in which the CBG-binding capacity has been 
determined. One of the samples is consistently discordant 
in the 9G12 ELISA, whereas the other is consistently 
concordant between all assays.
Purification of plasma CBG
Plasma samples treated with DCC to remove endogenous 
steroids were applied to an 11β-hydroxy-andros-4-en-3-
oxo-17β-carboxylic acid Sepharose affinity gel (Robinson 
et al. 1985). After washing the gel with 100 mM Tris–NaCl, 
pH 7.4, containing 1 mM EDTA, steroid-bound CBG was 
eluted with 1 μM cortisol, in the same buffer, for analysis.
Immunoaffinity depletion of CBG with an intact  
RCL epitope
The reference plasma sample in which CBG measurement 
in the 9G12 ELISA is highly discordant with 12G2 ELISA 
values was incubated with Protein-A affinity-purified 
9G12 Mab (that recognizes only CBG with an intact 
RCL) overnight at 4°C. The mixture was then incubated 
with purified rabbit anti-mouse IgG antibodies (Sigma-
Aldrich) coupled to NHS-activated Sepharose for 4 h 
at room temperature (GE Healthcare). The Sepharose 
immunoaffinity gel was sedimented by centrifugation 
and the supernatant was retained for analysis of CBG 
by ELISAs and steroid-binding capacity, as described 
earlier. In addition, the plasma sample was applied to a 
steroid-affinity gel prior to immunoprecipitation, and the 
semi-purified CBG was subjected to ELISAs to confirm 
that the discrepancy in ELISA values remained prior to 
immunoprecipitation with 9G12, as above.
Biochemical analyses of CBG
A heat-dependent polymerization assay was used to 
identify RCL-cleaved CBG in plasma samples (Gardill 
et al. 2012). In brief, plasma was subjected to incremental 
increases in temperature (0.1°C/s to 70°C), prior to non-
denaturing PAGE, and proteins in the electrophoresis gel 
were transferred to PVDF membranes using a Trans-Blot 
turbo transfer system (BioRad). The blots were blocked 
with 5% milk-PBST and incubated overnight at 4°C with 
a rabbit anti-human CBG antiserum (Robinson et  al. 
1985) diluted 1:4000 in 5% milk-PBST. Immunoreactive 
CBG was detected using horseradish peroxidase-labeled 
goat anti-rabbit IgG antibody (1:10,000; Sigma-Aldrich) 
for 1 h at room temperature, and ECL reagent using an 
ImageQuant LAS4000 (GE Healthcare). As a control in 
this assay, corresponding plasma samples were incubated 
with NE (Elastin Products Company) under conditions 
that specifically cleave the RCL of human CBG (Simard 
et al. 2014).
Denaturing SDS-PAGE (10% resolving gels) was 
performed on steroid-affinity gel purified CBG preparations 
(see above). Western blots were blocked and probed as 
described above. Rabbit anti-human CBG antibodies were 
affinity purified from antiserum (Robinson et  al. 1985) 
using an E. coli expressed human CBG-GST fusion protein 
(Gardill et al. 2012) coupled to NHS-activated Sepharose 
(GE Healthcare).
Mass spectrometry
Steroid affinity-purified CBG (6 µg) was digested 
(100:1 w/w) with trypsin (Promega) for 16 h in ammonium 
bicarbonate buffer, pH 8. As a positive control, purified 
CBG was incubated with human NE (10 min, 37°C) 
prior to trypsin digestion. Tryptic peptides were desalted 
using C18 stage tips (Supelco) and analyzed by liquid 
chromatography using an Easy nLC-1000 (Thermo 
Fisher Scientific) coupled to an Impact II QTOF tandem 
mass spectrometer equipped with a CaptiveSpray ion 
source (Bruker Daltonics). Desalted peptides (1 µg) were 
loaded onto an in-house packed column with 1.9 µm C18 
ReproSil-Pur (Dr Maisch GmbH) and resolved using a 
linear gradient of 5–24% buffer B (100% acetonitrile) over 
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60 min. For peptide identification, a top 17 method was 
used, with the normalized fragmentation energy at 27%. 
Survey and fragment spectra were analyzed with Byonic v 
2.16.11 (Protein Metrics).
Statistical analyses
Arterio-venous data were analyzed by Wilcoxon signed-
rank test and by Mann–Whitney U test. ICU patient data 
were analyzed using ANOVA, followed by Dunnett’s 
post hoc tests to examine significant main effects. Data are 
expressed as mean ± s.d. and differences were considered 
significant at P ≤ 0.05. Correlations were analyzed using 
linear regression and the corresponding r2-value and best-
fit linear regression line are provided in the results and 
figures, respectively.
Results
Comparisons of ELISA and cortisol-binding capacity 
measurements of CBG
When ELISA and cortisol-binding capacity measurements 
of CBG in plasma samples from the CROATIA-Korcula 
cohort were analyzed, the 12G2 ELISA and cortisol-
binding capacity measurements were always concordant, 
while 9G12 ELISA values in a subset of 10 individuals 
were ~50% lower than the corresponding cortisol-binding 
capacity values (Fig. 1A). Included within these assays are 
two reference plasma samples in which the 9G12 ELISA 
and cortisol-binding capacity values are consistently 
either concordant or discordant. These samples were 
also used as standards for comparisons of CBG ELISA 
and cortisol-binding capacity measurements in other 
studies (see below). When the two different ELISA values 
were compared with each other, a similar distribution of 
concordance and discordance was observed (Fig. 1B).
Measurements of plasma CBG by ELISAs and  
cortisol-binding capacity are consistent in arterial 
and venous blood samples from the same individual
To determine if there were any variations in ELISA or 
cortisol-binding capacity measurements of CBG across 
individual tissues, arterial plasma samples and venous 
plasma samples from veins draining forearm skeletal 
muscle, subcutaneous adipose, liver and brain were 
collected. Of particular interest was adipose tissue, as 
differences in the levels of CBG across the tissue bed were 
anticipated in obese individuals, due to the presence of 
activated neutrophils. Within each group of samples, 
comparisons of arterial and venous CBG values obtained 
using the 12G2 ELISA with the corresponding cortisol-
binding capacity values showed close correlations 
and concordance in skeletal muscle (Fig.  2A), adipose 
(Fig. 2C), liver (Fig. 2E) and brain (Fig. 2G). By contrast, 
the 9G12 ELISA values correlated less well with cortisol-
binding capacity and 12G2 ELISA values in skeletal 
muscle (Fig.  2A and B), adipose (Fig.  2C and D), liver 
(Fig.  2E and F) and brain (Fig.  2G and H). The weak 
correlation between 9G12 ELISA values in comparison 
to cortisol-binding capacity and 12G2 ELISA values can 
be explained by ~25–50% lower 9G12 ELISA values in a 
subset of samples.
Considering the arterio-venous differences across 
tissues, there were no gradients in cortisol-binding 
capacity measurements (Fig.  3A, D and G), 12G2 ELISA 
(Fig. 3B, E and H) or 9G12 ELISA values (Fig. 3C, F and 
I). In addition, after correction for blood flow, the only 
significant net uptake or release of CBG from individual 
tissues was detected across liver, where obese men with 
type 2 diabetes had net release of CBG as measured by 
cortisol-binding capacity (Supplementary Table  1). 
Notably, plasma CBG levels remained consistent when 
comparing arterial samples to blood collected from an 
adipose vein in a subset of obese individuals (Fig.  3A, 
B and C), suggesting that RCL cleavage does not occur 
across this tissue bed.
Figure 1
Despite differences in ELISA values in a subset of samples, CBG-cortisol 
binding capacities are normal. Comparisons of plasma CBG levels 
measured using two different ELISAs and a [3H]-cortisol-binding-capacity 
assay in 20 healthy individuals from the CROATIA-Korcula cohort. (A) In all 
samples, CBG values obtained by cortisol-binding capacity assay and 
12G2 ELISA show a close correspondence (circles) with the dashed line 
indicating a perfect correspondence between values. In most samples, 
cortisol-binding capacity and 9G12 ELISA values closely align and are 
designated concordant (triangles). (A and B) In a subset of samples, 9G12 
ELISA values are 50–60% lower than corresponding cortisol-binding 
capacity (A) or 12G2 ELISA values (B) and are designated discordant 
(squares). Included are two reference samples, in which the 9G12 ELISA 
and cortisol-binding capacity values are consistently either concordant 
(labeled C) or discordant (labeled D).
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No evidence for RCL cleavage of CBG in plasma 
samples
In an attempt to identify CBG with a cleaved RCL in blood, 
we first used a cortisol-binding capacity assay to measure 
plasma CBG levels in ICU patients (Supplementary 
Table 2 for patient demographics) with a variety of acute 
infections and/or inflammation, in whom activated 
neutrophils capable of cleaving the RCL of CBG were 
expected because of the severity of their disease.
No significant differences in plasma CBG-cortisol 
binding capacity were found in the different patient 
populations (Fig. 4A). When compared to the average plasma 
CBG-cortisol-binding capacity of healthy individuals 
(n = 316) from the CROATIA-Korcula cohort (Bolton et  al. 
2014), significantly lower CBG-cortisol-binding capacity 
values were detected in the ICU patients (P = 0.0039), with 
significant differences found in sub-groups of patients 
with gastroenterological, respiratory and other diagnoses 
(P < 0.05), as well as in those with sepsis, surgical abdominal 
and trauma diagnoses (P < 0.01) (Fig. 4A).
When the 12G2 ELISA and cortisol-binding capacity 
assay values in these patients were compared (Fig. 4B), they 
correlated (r2 = 0.635) and aligned well with each other. 
However, correlations between CBG levels determined by 
9G12 ELISA, and CBG-cortisol-binding capacity (Fig. 4C) 
or 12G2 ELISA (Fig. 4D) were very weak (r2 = 0.1830 and 
0.1427, respectively), and this discordancy was unrelated 
to the severity of the patients’ clinical condition.
Human CBG with a cleaved RCL is undetectable in ICU 
samples with discordant ELISA values
Based on the premise that acutely ill patients with a 
discordancy in their plasma CBG levels by ELISAs reflects 
the presence of CBG with a cleaved RCL, we analyzed five 
ICU samples that exhibited a large discrepancy in 9G12 
ELISA values and two ICU samples in which all CBG 
measurements were concordant. When the 12G2 and 
9G12 ELISA values were compared in these samples pre- 
(Fig. 5A) and post- (Fig. 5B) steroid-affinity purification, a 
similar relationship was observed; two samples (ICU 2 and 
ICU 6) were concordant, while five ICU patients displayed 
a discordancy in the 9G12 ELISA values that ranged from 
30 to 50% of the corresponding 12G2 ELISA values.
To optimize the resolution and accuracy of western 
blotting procedures, we affinity purified a rabbit anti-
human CBG antibody (see Materials and methods) and 
used a steroid-affinity gel to isolate CBG from plasma 
samples. As a control, NE was used to cleave the RCL of 
CBG prior to steroid-affinity chromatography and western 
blot analysis. The resulting western blot shows that 
NE-cleaved CBG was retained and purified by the steroid-
affinity gel despite its relatively low steroid-binding affinity, 
which was undetectable in the cortisol-binding capacity 
assay (Fig. 5C). As expected, the apparent molecular size 
of NE-cleaved CBG is also ~4 kDa smaller than the major 
immunoreactive forms of CBG in the ICU patient samples. 
Figure 2
Plasma cortisol-binding capacity and 12G2 ELISA values show the 
strongest correlation. Blood samples were collected from a peripheral 
‘arterialised’ vein from a heated hand (A, B, C, D, E, F, G and H), as well as 
from veins draining forearm skeletal muscle (A and B; n = 18), abdominal 
subcutaneous adipose (C and D; n = 18), liver (hepatic vein; E and F; 
n = 17) and brain (internal jugular vein; G and H; n = 8) veins and assayed 
for CBG levels. Data were analyzed using linear regression and the r2 
value and P-value are provided with each graph. (A, C, E and G) Within 
each group of combined arterial and venous samples from each cohort, 
CBG-cortisol binding capacity measurements were correlated more 
strongly with 12G2 ELISA values than with 9G12 ELISA values. (B, D, F 
and H) The correlation between the 12G2 and 9G12 ELISA values was 
also less strong than the correlation between 12G2 and cortisol-binding 
capacity measurements.
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Figure 3
Plasma CBG measurements are consistent across 
different sites of blood sampling. Blood samples 
were collected from a peripheral ‘arterialised’ vein 
from a heated hand (A, B, C, D, E, F, G, H and I), as 
well as from veins draining forearm skeletal 
muscle (A, B and C; n = 18), abdominal 
subcutaneous adipose adipose (A, B and C; 
n = 17), liver (hepatic vein; D, E and F; n = 16) and 
brain (internal jugular vein; G, H and I; n = 8) veins, 
and assayed for CBG levels. Plasma CBG levels 
measured by cortisol-binding capacity (A, D and 
G), 12G2 ELISA (B, E and H) and 9G12 ELISA (C, F 
and I) are consistent across the different sites of 
blood sampling in a given individual.
Figure 4
In ICU patient samples, decreased cortisol-binding 
capacity levels are observed, but a high 
correspondence with 12G2 ELISA values suggests 
RCL-cleaved CBG is not present. (A) Plasma 
CBG-cortisol binding capacity in various ICU 
patient populations. Box plots for each patient 
group display the maximum, third quartile, 
median, first quartile and minimum, with the 
mean included as a dashed line. CBG-cortisol 
binding capacity values were compared to the 
mean of a healthy control population (mean ± s.d., 
dashed line and shaded grey), and significant 
differences were detected (main effect of 
diagnosis by ANOVA, P = 0.0039). Significantly 
lower CBG levels were found in patients with 
gastroenterological, respiratory and other 
diagnoses (*P < 0.05), as well as individuals with 
sepsis, surgical abdominal and trauma diagnoses 
(**P < 0.01). Data in A is presented as mean ± s.d. 
Dunnett’s post hoc: *P < 0.05, **P < 0.01. Plasma 
CBG levels were measured by cortisol-binding 
capacity (B), 12G2 (C) and 9G12 (D) ELISAs, and 
data were analyzed using linear regression, with 
r2 values and P-values provided with each graph. 
(B) A strong correlation was found between 
cortisol-binding capacity and 12G2 ELISA values 
(r2 = 0.6351). (C) Weak correlations were observed 
between 9G12 ELISA and cortisol-binding capacity 
(r2 = 0.1427) or between the (D) 9G12 and 12G2 
ELISA values (r2 = 0.1830).
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Most importantly, the profiles of CBG in ICU patient 
plasma (e.g. ICU 2 and ICU 6) that show a concordance 
in their ELISA values, were identical to those observed 
in a normal control sample or in samples from patients 
that exhibit a discordance in their ELISA values, with no 
evidence of NE-cleaved CBG in any samples (Fig. 5C).
Samples in which 9G12 ELISA values were either 
concordant (C) or ~50% discordant (D), when compared 
with the corresponding cortisol-binding capacity or 
12G2 ELISA values (Fig. 1), were also subjected to a heat-
dependent polymerization assay that detects CBG with 
a cleaved RCL (Gardill et  al. 2012). In this assay, CBG 
molecules with an intact RCL polymerize and run with a 
slow mobility during native PAGE, while the electrophoretic 
mobility of CBG with a cleaved RCL is much faster, and it 
migrates much further into the gel (Fig. 6A). This analysis 
demonstrated that while NE can effectively cleave CBG in 
both samples, there is no evidence of CBG proteolysis in 
the ELISA discordant sample. Furthermore, when subjected 
to Scatchard analysis (Fig.  6B), CBG in the concordant 
and discordant samples bound [3H]-cortisol with similar 
affinities (Kd=0.23 and 0.21 nM, respectively), and these 
values were similar to those measured in other samples 
using the same assay (Smith et al. 1992). In addition, the 
Bmax value for sample C was almost twice as high as for 
sample D, which was in line with their respective cortisol-
binding capacity and 12G2 ELISA values (Fig. 1C).
Plasma CBG that is not recognized by the 9G12 Mab 
has a normal steroid-binding activity
In addition, we sought to characterize the molecular and 
biochemical properties of CBG that is not recognized by 
the 9G12 Mab. To accomplish this, a reference plasma 
sample in which the 9G12 ELISA value is consistently 
~50% discordant (Fig.  7A) was incubated with purified 
9G12 Mab, and CBG-antibody complexes were 
immunoprecipitated with Sepharose coupled rabbit-
anti mouse IgG. When CBG in the supernatant was 
analyzed in the ELISAs, it was readily detected using the 
12G2 Mab, while 9G12 immunoreactive CBG levels were 
barely detectable (Fig.  7A). Therefore, if the 9G12 Mab 
only detects CBG with an intact RCL, the RCL of CBG 
in the supernatant after immunoprecipitation with the 
9G12 Mab should be cleaved with a low steroid-binding 
affinity, but its affinity for corticosterone (Kd = 0.27 nM) 
Figure 5
Following steroid-affinity purification, ICU samples 
remain discordant in the 9G12 ELISA, without 
evidence for CBG cleavage by western blotting. 
CBG from ICU patient plasma was purified using a 
steroid-affinity gel and assayed for CBG levels and 
protein integrity. The relationship between 12G2 
and 9G12 ELISA values was consistent pre- (A) and 
post- (B) affinity purification; i.e. ICU samples that 
were concordant (ICU 2 and ICU 6) or discordant, 
respectively, remain so following purification. (C) 
Plasma CBG integrity was analyzed by western 
blotting. As controls, a sample from a healthy 
individual, untreated (CTL) or treated with NE (NE 
CTL), was included. As expected, following 
incubation with NE, the apparent molecular size 
of CBG shifted ~4 kDa downwards, and this shift 
was not observed in any of the ICU patient 
plasma samples. For each sample, cortisol-
binding capacity assay values are provided for 
comparison; note the lack of CBG-cortisol binding 
capacity in the NE-treated sample.
Figure 6
No evidence for RCL cleavage or low affinity CBG in a sample with a 
discordant CBG 9G12 ELISA value. (A) When analyzed in a heat-dependent 
polymerization assay, no differences were observed between a 
discordant (labeled D) and concordant (labeled C) sample. Under these 
conditions, CBG with an intact RCL polymerizes (solid arrow) while CBG 
with an RCL that is cleaved by NE does not (open arrow). This provides 
evidence for a lack of CBG cleavage in these samples, while NE cleavage 
clearly results in the expected changes in electrophoretic mobility in both 
samples. (B) No differences in the cortisol-binding affinity (Kd) of plasma 
CBG were observed in samples with concordant or discordant 9G12 ELISA 
values; Kd = 0.21 and 0.23 nM, respectively.
This work is licensed under a Creative Commons 
Attribution 4.0 Unported License.https://doi.org/10.1530/JOE-18-0479
https://joe.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd.
Printed in Great Britain Downloaded from Bioscientifica.com at 01/15/2019 09:21:23AM
via University of Edinburgh and MULTI-PFIZER
34Absence of NE-cleaved, low-
affinity plasma CBG
L A Hill et al. 240:1Journal of 
Endocrinology
was similar to that of plasma CBG (Kd = 0.24 nM) prior to 
immunoprecipitation (Fig. 7B).
In other experiments using the same ELISA discordant 
sample, CBG was first purified from plasma using a steroid-
affinity gel, and measured in the 12G2 and 9G12 ELISAs 
to verify that the discordancy was preserved (Fig.  7C). 
The affinity-purified CBG was then immunoprecipitated 
using the 9G12 Mab and the remaining CBG in the 
supernatant was analyzed in the 12G2 and 9G12 
ELISAs. In the supernatant, CBG was easily detected 
using the 12G2 Mab, while 9G12 immunoreactive CBG 
was undetectable (Fig.  7C). Similar to the results seen 
in plasma, Scatchard analysis demonstrated that the 
affinity of CBG for corticosterone in the supernatant 
(post immunoprecipitation, Kd = 1.75 nM) was similar 
to that of steroid-affinity gel purified CBG (pre 
immunoprecipitation, Kd = 1.72 nM) (Fig.  7D). A lack of 
cleaved CBG in the supernatant was confirmed using 
SDS-PAGE (Fig.  7E). The higher steroid-binding affinity 
of purified CBG in comparison to plasma is due to the 
absence of contaminating albumin, which alters the 
bound-to-free ratio in Scatchard plots.
NE-cleaved CBG is not present in plasma with a 
discrepant 9G12 value
Finally, mass spectrometry and peptide analyses were 
used to determine if RCL-cleaved CBG is present in 
plasma with a highly discrepant 9G12 value. We obtained 
93% sequence coverage of purified human plasma CBG. 
As a positive control, purified CBG was incubated with 
NE, and we identified the non-prime NE-cleaved semi-
tryptic peptide (326K.AVLQLNEEGVDTAGSTGV.T345) 
(Fig. 8B; Supplementary Fig. 1C), as well as a prime side 
cleavage product (344V.TLNLTSKPIILR.F356) (Fig.  8B; 
Supplementary Fig. 1D). However, these peptides were not 
identified in untreated purified CBG (Fig. 8A; Supplementary 
Fig. 1A and B). In human plasma, the intact RCL peptide 
(326K.AVLQLNEEGVDTAGSTGVTLNLTSKPIILR.F356) 
spanning the NE cleavage site was the dominant peptide 
identified (Fig. 8A; Supplementary Fig. 1B). N-glycosylation 
at Asn347 was detected in tryptic peptides spanning the 
RCL, confirming occupancy of N-glycans at this site in 
vivo, with the major glycans observed being sialylated 
bi-antennary oligosaccharides. Low abundance peptides 
corresponding to a proteolytic processing event at Asn347 
were identified, but this was not surprising given that low 
levels of spurious cleavage may occur during extensive 
CBG purification or analysis (Gardill et al. 2012). Hence, 
steady state levels of NE-cleaved CBG are not present in 
human plasma.
Discussion
Proteolytically cleaved CBG has been observed in 
bronchoalveolar lavage fluid of patients with inflammatory 
lung disease, while CBG cleavage products were absent in 
serum from the same patients (Williams et al. 2009). Low 
serum levels of CBG have been demonstrated by CBG 
Figure 7
Plasma CBG that is not recognized in the 9G12 ELISA binds steroid with 
normal affinity and has a molecular size consistent with uncleaved CBG. 
Plasma samples were incubated with purified 9G12 to immunoprecipitate 
RCL-intact CBG using Sepharose-coupled rabbit anti-mouse IgG, and the 
supernatants were collected for analyses. (A) ELISA measurements were 
performed on a sample known to be discordant in the 9G12 ELISA, prior 
to immunoprecipitation (pre) and after 9G12-reactive CBG was 
immunoprecipitated (post). (B) The corresponding Scatchard plots of CBG 
in samples pre- and post- immunoprecipitation demonstrate a similar 
affinity for steroid (Kd = 0.24 and 0.27 nM, respectively). (C) This highly 
discordant sample was also subjected to steroid-affinity purification prior 
to 9G12 immunoprecipitation and the discordancy between the ELISA 
values was unchanged. Steroid-affinity purified CBG was detected in the 
12G2 ELISA following immunoprecipitation with the 9G12 Mab but was 
not detectable using the 9G12 ELISA, as expected. (D) Scatchard analysis 
demonstrated that steroid-affinity purified CBG binds corticosterone with 
a similar affinity in the sample prior to (pre, Kd = 1.72 nM) and after (post, 
(Kd = 1.75 nM) 9G12 immunoprecipitation. (E) The integrity of CBG in the 
samples pre- and post- 9G12 immunoprecipitation was also assessed by 
western blotting and compared with NE-cleaved CBG that is characterized 
by an ~4 kDa reduction in molecular size. Note there is no evidence of 
immunoreactive CBG with a molecular size consistent with NE-cleavage, 
in either the pre- or post- 9G12 immunoprecipitation samples. In the post 
sample, there is a faint band at ~50 kDa, which is specifically recognized 
by the goat anti-rabbit IgG antiserum used for western blotting, and this 
represents a trace amount of rabbit anti-mouse IgG that leaches from the 
Sepharose immunoaffinity gel.
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cortisol-binding capacity and RIA in patients with septic 
shock (Pugeat et al. 1989). Precipitous decreases in plasma 
CBG levels observed during acute infections, trauma or 
severe inflammation (Zouaghi 1984, Bernier et al. 1998) 
are thought to reflect NE cleavage of the CBG RCL and 
disruption of its steroid-binding affinity (Hammond 
et  al. 1990). Although granulocytes from patients with 
severe acute inflammation also cleave and disrupt the 
steroid-binding activity of CBG, while those from healthy 
individuals do not (Hammond et  al. 1990), the fate of 
CBG in the blood circulation of acutely ill patients after 
the proteolysis of its RCL remains enigmatic.
This is an important question, especially in light 
of numerous reports suggesting that RCL-cleaved CBG 
within the blood (Nenke et al. 2015, 2016a,b,c, 2017a,b) 
makes up to 30% of total plasma CBG, even in healthy 
individuals (Lewis & Elder 2011). However, reduced levels 
of RCL-cleaved CBG inferred from ELISA measurements 
in patients with abdominal obesity (Nenke et al. 2016a), 
alpha-1-antitrypsin deficiency (Nenke et  al. 2016b) 
and active rheumatoid arthritis (Nenke et  al. 2016c) are 
paradoxical and hard to reconcile because activated 
neutrophils in these patients would be expected to 
increase CBG cleavage. Evidence for RCL-cleaved CBG 
within the circulation in these studies has been based 
solely on differences between CBG measurements in two 
ELISAs that rely on different monoclonal antibodies for 
CBG detection (Lewis et  al. 2003, Lewis & Elder 2011), 
and our biochemical analyses have now demonstrated 
that discrepancies in these two ELISAs do not reflect 
abnormalities in the steroid-binding affinity of human 
CBG or proteolysis of its RCL. Moreover, we have been 
unable to detect RCL-cleaved CBG in blood samples from 
acutely ill patients with very low plasma CBG levels or 
in blood samples in which there is a marked discrepancy 
in CBG levels measured using an ELISA that employs 
a monoclonal antibody designed to recognize CBG 
molecules with an intact RCL (Lewis & Elder 2011).
Assays of CBG based on functional measurements of 
its steroid-binding capacity or immunoreactivity both 
have inherent limitations. Steroid-binding capacity 
measurements rely on the saturation of a single steroid-
binding site per CBG molecule, and the amount of 
bound ligand is therefore assumed to directly reflect 
the molar concentration of the protein. In our steroid-
binding capacity assay, DCC is used to adsorb non-CBG 
bound radio-labeled ligand, and irreversible losses of 
CBG-bound ligands occur during this process and have 
to be accounted for (Hammond & Lahteenmaki 1983). 
This allows for the identification of CBG mutants with 
abnormally low steroid-binding affinity, and NE-cleaved 
CBG with an ~10-fold reduction in steroid-binding 
affinity is undetectable in this assay (Simard et al. 2015), 
as also demonstrated here (Fig.  5C). Thus, if the 9G12 
ELISA detects only CBG with an intact RCL and a high 
affinity for cortisol, the 9G12 values should closely align 
with the cortisol-binding capacity values, and in many 
cases they do not.
By contrast, samples that show ~30–50% discordance 
between 9G12 ELISA and cortisol-binding capacity values, 
have corresponding 12G2 ELISA values that align closely 
with cortisol-binding capacity values. In the samples 
studied, we observed the strongest correlation between 
plasma CBG levels measured by cortisol-binding capacity 
and 12G2 ELISA, and this provided an indication that the 
discrepancy in ELISA values has nothing to do with an 
abnormality in steroid-binding activity, but rather hints 
at a variance in 9G12 monoclonal antibody recognition.
Figure 8
9G12 ELISA discrepant plasma CBG has an intact RCL as identified by high-resolution mass spectrometry. Affinity-purified plasma CBG was trypsin 
digested and the resulting peptides were identified by LC-MS and analyzed with Byonic v2.16.11. As a positive control for RCL cleavage, CBG was first 
incubated with NE (10 min). RCL spanning peptides identified by LC-MS in (A) plasma CBG and (B) NE-cleaved plasma CBG samples. Cleavage sites 
corresponding to NE, trypsin and an unknown protease are shown. Spectral counts were used as a surrogate of peptide abundance. At Asn347, the most 
common N-glycan identified was sialylated and biantennary, and this is shown for reference.
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In most of the blood samples analyzed, the CBG 
measurements by the three different assays correlated and 
aligned well with each other, but highly discordant 9G12 
ELISA values were observed in a subset of samples. This 
discordance in 9G12 ELISA values was unrelated to the site 
of blood collection or the health status of the individuals 
from whom the samples were taken. Moreover, this 
discordance in the ELISA or CBG-cortisol binding capacity 
values was consistently observed in samples collected at 
different anatomical locations, including skeletal muscle, 
adipose, liver and brain. Notably, CBG levels in obese 
individuals remained consistent across adipose tissue, in 
which activated neutrophils are expected to be present 
(Dam et al. 2016) and cause proteolysis of the CBG RCL.
Although it is clear that in vitro RCL-cleavage of CBG 
by NE disrupts high affinity cortisol binding (Pemberton 
et  al. 1988, Hammond et  al. 1990) and recognition by 
the 9G12 Mab (Lewis & Elder 2011), evidence that RCL-
cleaved CBG is retained within blood is circumstantial. To 
address this, we utilized a heat-dependent polymerization 
assay that detects NE-mediated RCL cleavage of CBG 
(Gardill et al. 2012), but found no evidence of RCL-cleaved 
CBG in a sample in which the 9G12 ELISA value is highly 
discordant. Further evidence for a lack of RCL-cleaved 
CBG with a low steroid-binding affinity in this ELISA 
discrepant sample was obtained by Scatchard analyses.
We used a steroid-affinity gel to purify CBG from 
plasma samples taken from critically ill patients in whom 
CBG levels were lower than normal, as the most likely 
patient group in which cleaved CBG was to be expected. 
When CBG purified from these patients was analyzed, the 
concordance or discordance between their ELISA values 
remained, and there was no evidence of RCL-cleaved CBG 
with an increased electrophoretic mobility by western 
blotting. By examining the biochemical properties of 
CBG in samples with a discrepancy in ELISA values, we 
also demonstrate that CBG that is not recognized by the 
monoclonal antibody (9G12) directed against an intact 
RCL has a normal affinity for cortisol, and the same 
molecular size as CBG with an intact RCL. In other words, 
CBG that is undetected by the 9G12 ELISA has a high 
steroid-binding affinity and an intact RCL. The absence of 
NE-cleaved CBG in human plasma was further confirmed 
by high-resolution mass spectrometry.
While we present direct evidence that CBG with a 
cleaved RCL and a low affinity for cortisol is not present 
in human plasma samples, we still do not know what 
happens to CBG after its RCL is cleaved in vivo. Studies 
of the plasma clearance of native, RCL-cleaved and 
protease-complexed forms of SERPINA1, indicated that 
RCL-cleaved SERPINA1 is cleared from the circulation 
more rapidly than the intact protein, but not as rapidly 
as the SERPINA1–protease complex (Mast et  al. 1991). 
Moreover, the mechanism responsible for the clearance 
of RCL-cleaved SERPINA1 appeared to be unrelated to 
that responsible for the clearance of SERPINA1-protease 
complexes (Mast et al. 1991), which is known to involve 
a multifunctional scavenging and signaling receptor, 
the low-density lipoprotein receptor-related protein 1 
(Strickland et al. 2011). The plasma clearance of CBG and 
SERPINA1 may behave similarly after cleavage of their 
RCLs, but this remains to be determined.
Why CBG in blood samples from some individuals 
behave anomalously in the ELISAs we and others have 
used remains to be defined, but it is clear that the epitope 
recognized by the 9G12 monoclonal antibody includes 
the residues (STGVTLNL) between Ser341 and Leu348 of 
human CBG and spans the NE cleavage site after Val344 
(Lewis & Elder 2011). The C-terminal portion of this 
epitope sequence also contains part of an N-glycosylation 
sequence (NL-T), which is utilized in approximately 85% 
of plasma CBG molecules (Sumer-Bayraktar et al. 2011). 
The N-glycan at this position is also heterogeneous with 
a relatively high degree of fucosylation (35%) and bi-, 
tri- or tetra-antennary oligosaccharide structures (Sumer-
Bayraktar et  al. 2011), and this variability has been 
reported to influence the protease recognition and/or 
cleavage of the RCL (Sumer-Bayraktar et  al. 2016). This 
is particularly relevant because the synthetic polypeptide 
used to develop the 9G12 monoclonal antibody was 
not glycosylated, and recognition of this epitope is 
likely influenced by the presence or absence of different 
N-glycans attached to the RCL sequence. In support of 
this, a naturally occurring CBG T349A variant exhibits 
unexpectedly high values in the 9G12 ELISA when 
compared to the 12G2 ELISA (Simard et  al. 2015). We 
attribute this apparent increase in the reactivity of CBG 
T349A in the 9G12 ELISA to the fact that Thr349 is located 
just outside of the 9G12 epitope and its substitution 
with alanine disrupts N-glycosylation at Asn347, making 
the epitope more accessible to the 9G12 monoclonal 
antibody. In contrast, the 12G2 monoclonal antibody was 
raised using CBG as the antigen and appears to recognize 
an epitope that includes Ala256, which was deduced 
from the observation that CBG A256T is not recognized 
in the 12G2 ELISA (Simard et  al. 2015). The fact that 
this residue is located within a structurally constrained 
region on the surface of CBG may explain why there is an 
excellent correlation and alignment between 12G2 ELISA 
and steroid-binding capacity assay values.
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Although N-glycosylation within the RCL might 
influence the ability of the 9G12 monoclonal antibody 
to recognize its epitope, the overall structure of the 
RCL is also thought to be dynamic and unstructured, 
and its positioning may be altered by occupancy of the 
steroid-binding site (Lin et al. 2009, 2010). Furthermore, 
we recently reported that quantitative and qualitative 
differences in N-glycosylation at other sites in the CBG 
molecule may influence its structure and steroid-binding 
properties, and predicted that this may influence CBG 
recognition by specific monoclonal antibodies (Simard 
et  al. 2018). This might explain why measurements 
of CBG by RIAs, which use polyclonal antibodies that 
recognize a large number of epitopes, are closely aligned 
with cortisol-binding capacity measurements (Robinson 
& Hammond 1985).
Discrepancies in the ELISAs utilized have been 
associated with specific SNPs within the SERPINA6 gene, 
and it appears that the recognition of CBG in the 9G12 ELISA 
is influenced by rs12589136, which is located upstream of 
the SERPINA6 transcription start site close to a consensus 
estrogen response element (Bolton et al. 2014). Although 
it has been suggested that estrogen dependent increases 
in CBG production might account for differences in 9G12 
monoclonal antibody recognition, for instance during 
pregnancy or oral contraceptive use (Nenke et al. 2017b), 
there are no obvious sex differences in the frequency 
of the discordancy in these ELISA measurements. It is 
therefore possible that linkage disequilibrium between 
rs12589136 and another polymorphism in another gene 
influences the structure of CBG, for instance as the result 
of a post-translational modification, in ways that alter 
9G12 monoclonal antibody recognition of its epitope in 
the CBG RCL.
In summary, our studies, utilizing a variety of 
complementary, highly sensitive and orthogonal 
approaches, including high-resolution mass spectrometry, 
indicate that human CBG with a NE-cleaved RCL is 
undetectable in blood samples, even from acutely ill 
patients. Interestingly, we have demonstrated that during 
acute inflammation in rats, CBG with a cleaved RCL and 
undetectable steroid binding is retained in the blood 
circulation (Hill et  al. 2016), and this is quite different 
to what we see in critically ill humans. It is possible that 
the structural changes in CBG after RCL cleavage during 
acute inflammation in humans and rats are different, 
or that there are species differences in the clearance 
mechanisms for RCL-cleaved CBG. The question of the 
fate of human CBG after RCL cleavage by NE therefore 
remains to be resolved.
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